# Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

> **NCT04053634** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 689 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04053634
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-26
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053634, "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04053634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*